Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Label Expansion: Could Clinical Experience Data Find Supplement Work-Around?

Executive Summary

Friends of Cancer Research seeks way of allowing high-quality efficacy data into label when supplemental NDA is not feasible.

You may also be interested in...



Will Antimicrobial Breakpoint Changes Signal Shift To Online Labeling Updates?

FDA must place antimicrobial breakpoints that usually appear in labeling on a website so they can be more regularly updated. CDER Director Woodcock said that could become a precedent for other electronic labeling changes.

Woodcock Wants Rapid Regulatory Policy Development

CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.

Woodcock Wants Rapid Regulatory Policy Development

CDER Director says US FDA needs to develop statistical and other guidances faster to keep up with the pace of science and drug development.

Related Content

Topics

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel